DelveInsight’s, “Osteoarthritis Pipeline Insights 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Osteoarthritis Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight

Key Takeaways from the Osteoarthritis Pipeline Report

• On May 22, 2026, Eli Lilly and Company initiated a phase 3 study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
• On May 06, 2026, Kolon TissueGene Inc. announced a phase 3 study to determine the efficacy and safety of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.
• DelveInsight’s Osteoarthritis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Osteoarthritis treatment.
• The leading Osteoarthritis Companies such as Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others.
• Promising Osteoarthritis Pipeline Therapies such as MK0663, Etoricoxib, Diacerein, Celecoxib, RTX-GRT7039, Naproxcinod, Naproxen, LY3857210, LY3556050, LY3016859, Ibuprofen, Voltaren® Gel, Gevokizumab and others.

Access DelveInsight’s in-depth Osteoarthritis Pipeline Analysis for a closer look at promising breakthroughs @ Osteoarthritis Clinical Trials and Studies

Osteoarthritis Overview

Osteoarthritis is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work. Osteoarthritis is the most common type of arthritis, characterized by the gradual breakdown of cartilage in joints, leading to pain, stiffness, and swelling. Symptoms often include joint pain that worsens with activity and improves with rest, stiffness lasting less than 30 minutes after inactivity, and a sensation of joint instability or looseness. Affected joints may also produce a grinding or creaking sound during movement, and swelling can occur, particularly after prolonged use.

Osteoarthritis Emerging Drugs Profile

• Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. The drug is currently in Phase III stage of clinical trial evaluation to treat the patients suffering from osteoarthritis.

• EP-104IAR: Eupraxia Pharmaceuticals

Eupraxia’s lead product candidate, EP-104IAR, is designed to meet the significant unmet medical need and market demand for long-lasting disease relief in multiple indications benefitting from highly localized and longer delivery of corticosteroids. The lead indication is for pain relief in knee OA. EP-104IAR is designed to prolong the duration of pain relief with fewer unwanted side effects. It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane, part of Eupraxia’s patented technology platform. Injected into the knee, EP-104IAR is designed to diffuse the corticosteroid slowly into the knee joint providing local therapeutic concentrations for up to six months. This has the potential dual advantage of providing longer duration of pain relief with fewer systemic side effects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

• DFV890: Novartis

DFV890 is a small molecule, NOD-like receptor protein 3 (NLRP3) antagonist being developed by Novartis for the treatment of various inflammatory conditions. It is currently being evaluated in several phase I and II clinical trials, including studies in myeloid diseases, knee osteoarthritis, COVID-19, and cardiovascular disease. DFV890 works by inhibiting the NLRP3 protein, which plays a key role in the activation of the inflammatory response. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

• 4P004: 4P-Pharma

4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties. 4P004 was developed in collaboration with the team of Prof. Francis Berenbaum and SATT Lutech. 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

• GNSC 001: Genascence

GNSC-001 is a genetic medicine – a recombinant adeno-associated viral vector expressing an optimized form of IL-1Ra, a naturally occurring protein that blocks interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, as well as cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint. Currently, the drug is in Phase I stage of its clinical trial for the treatment of OA.

The Osteoarthritis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Osteoarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoarthritis Treatment.
• Osteoarthritis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoarthritis market.

Get a detailed analysis of the latest innovations in the Osteoarthritis pipeline @ Osteoarthritis Unmet Needs

Osteoarthritis Companies

Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others.

Osteoarthritis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Osteoarthritis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Osteoarthritis Therapies @ Osteoarthritis Market Drivers and Barriers, and Future Perspectives

Scope of the Osteoarthritis Pipeline Report

• Coverage- Global
• Osteoarthritis Companies- Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others.
• Osteoarthritis Pipeline Therapies- MK0663, Etoricoxib, Diacerein, Celecoxib, RTX-GRT7039, Naproxcinod, Naproxen, LY3857210, LY3556050, LY3016859, Ibuprofen, Voltaren® Gel, Gevokizumab and others.
• Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Osteoarthritis drug development? @ Osteoarthritis Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Osteoarthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Osteoarthritis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Lorecivivint: Biosplice Therapeutics
9. Mid Stage Products (Phase II)
10. EP-104IAR: Eupraxia Pharmaceuticals
11. Early Stage Products (Phase I)
12. GNSC 001: Genascence
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Osteoarthritis Key Companies
17. Osteoarthritis Key Products
18. Osteoarthritis- Unmet Needs
19. Osteoarthritis- Market Drivers and Barriers
20. Osteoarthritis- Future Perspectives and Conclusion
21. Osteoarthritis Analyst Views
22. Osteoarthritis Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight